TY  - GEN
AU  - Ueno,Fumiaki
AU  - Doi,Michio
AU  - Kawai,Yumi
AU  - Ukawa,Naoto
AU  - Cammarota,Jordan
AU  - Betts,Keith A
TI  - Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan
SN  - 1941-837X
PY  - 2020///0630
KW  - Adalimumab
KW  - economics
KW  - Biological Products
KW  - Clinical Trials, Phase III as Topic
KW  - Cost-Benefit Analysis
KW  - Crohn Disease
KW  - drug therapy
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Infliximab
KW  - Japan
KW  - Network Meta-Analysis
KW  - Randomized Controlled Trials as Topic
KW  - Remission Induction
KW  - Severity of Illness Index
KW  - Ustekinumab
N1  - Publication Type: Journal Article; Meta-Analysis
UR  - https://doi.org/10.1080/13696998.2019.1642900
ER  -